Ichnos Sciences has four sites around the globe—a biologics and early discovery research center in Lausanne, Switzerland; a biologics manufacturing and process sciences center in La Chaux-de-Fonds, Switzerland; an R&D Center in Mahape, India; and company headquarters in the United States in Paramus, New Jersey.
As the heart of our biologics innovation, our Research Center in Lausanne focuses on the discovery and development of new biological entities (NBEs) and is home to Ichnos’ groundbreaking BEAT® platform and a world-class, GMP-certified manufacturing line. Both Swiss research centers also house a full suite of in-house capabilities necessary for the discovery and development of new investigational biologics, from inception—including cell-line development, bioassay development and antibody engineering—through preclinical and early clinical studies.
The Ichnos Sciences R&D Center in Mahape, India, leverages internal scientific expertise, bringing forth new chemical entities (NCEs), from target selection to clinical development. The research facility is home to some of the most advanced technology needed for research activities, including medicinal chemistry, process and analytical chemistry, in vitro and in vivo studies, and project management.
Serving as the base of operations for the organization, corporate headquarters for Ichnos Sciences, located in New Jersey, includes the clinical sciences and development teams.
Ichnos Sciences is in the process of obtaining all the necessary statutory, legal, corporate and regulatory approvals for completion of the spin-off from Glenmark Holding SA.